Cantor Fitzgerald sets $140 price target for Celcuity
CELC Celcuity Inc
$65.57 +6.51%
View chart & analysis → - 1Cantor Fitzgerald initiated coverage on Celcuity with an Overweight rating and a price target of $140.
- 2Revatopik received approval for a 60% proportion of PIK3CA wild-type patients among the second-line treatment group.
- 3Revatopik is expected to reach peak sales of approximately $2.7 billion from the second-line indication alone.
So what's the key point?
Cantor Fitzgerald expects Celcuity's stock price to rise and has set a target of $140. Revatopik received approval for specific patients, which is expected to generate significant revenue.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.